Name: Julia Wang
New title: Executive vice president and CFO, Labcorp
Previous title: CFO, Beigene
Labcorp said Tuesday that Julia Wang will join the company on Dec. 2 as executive vice president and CFO, replacing Glenn Eisenberg.
Eisenberg will retire after 10 years as CFO. He will remain with the laboratory services provider as a special adviser to CEO Adam Schechter through April 2025 to help with the transition and strategic initiatives underway.
Wang is the former CFO at Beigene, where she is credited with accelerating growth while supporting innovation and a culture of sustainable operating efficiencies. She joined the oncology company in June 2020 as senior vice president for enterprise optimization and deputy CFO.
Schechter, in a statement, thanked Eisenberg for a “transformative” decade in which Labcorp’s revenues more than doubled from organic growth and acquisitions. Labcorp completed about 100 acquisitions during his tenure.
Evercore ISI analyst Elizabeth Anderson, in a note to clients, called Eisenberg an “institution” at Labcorp who helped lead the company through the COVID-19 pandemic and the 2023 spinoff of contract research organization Fortrea. Anderson predicted a smooth transition in the CFO’s office, highlighting Wang’s strong background in diagnostics and biopharma.
Labcorp said Wang brings to the position strategic and financial experience in the diagnostic, pharmaceutical/biotech, medical device and consumer products industries.
Before joining Beigene, Wang was senior vice president for global business finance and corporate planning at Alexion Pharmaceuticals and held leadership roles in finance at Quest Diagnostics. Before that, Wang was CFO of various operating businesses in medical devices and pharmaceuticals at Johnson & Johnson.
“We will benefit from Julia's extensive healthcare and consumer sector experience, strategic insights and operating rigor,” said Schechter.
